fbpx
 

Jaguar Animal Health Files for New Animal Drug with FDA


January 13, 2015

Jaguar Animal Health, Inc., an animal health company focused on developing and commercializing gastrointestinal products for companion and production animals, has initiated the filing of its first New Animal Drug Application (NADA) with the U.S. Food and Drug Administration (FDA).

The filing was submitted for Jaguar’s Canalevia prescription drug candidate, a proposed minor-use minor-species (MUMS) drug for use in dogs undergoing chemotherapy.

MUMS is an FDA drug designation, similar to the orphan drug designation in humans, which is typically limited to drugs that are used to treat a small number of animals each year.

Receipt of MUMS designation would allow Jaguar to make Canalevia commercially available before collecting all necessary effectiveness data, but only after proving the drug is safe and showing that there is a reasonable expectation of effectiveness.

Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. A human-specific formulation of crofelemer, Fulyzaq, was approved by the U.S. FDA in 2012 for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Share This Story On:

Stockroom //
New Products

Digital Guide

CBD Trends

This digital guide provides valuable information on the subject of CBD, including content on dosage and the importance of being fully transparent about the product’s origin

Pet Nutrition

Discover how science, technology and pet owning lifestyles are changing the industry.

Enews Subscribe

18382
close
Subscribe To Pet Age
Sign up for the weekly e-newsletter, print magazine and more. Sign Up